Printer Friendly

Circulating adiponectin and plasma fatty acid profile.

Adipose tissue is now known to secrete a myriad of proteins that are increasingly recognized to influence the metabolism of carbohydrates, proteins, and lipids (1). Adiponectin (also called Acrp30 or adipoQ in mice) is a 244-amino acid protein synthesized and secreted exclusively by the adipose tissue (2, 3). Adiponectin circulates at relatively high (mg/L) concentrations, and its half-life is in the range of several hours (4). This rate of turnover would be consistent with a role for this protein as a regulator of metabolic processes, such as modulation of fat partitioning, among other actions. Administration of adiponectin and/or its globular head portion stimulates free fatty acid oxidation in muscle (5). High fat feeding leads to decreased Acrp30 secretion in rodents (6), whereas caloric restriction leads to higher circulating concentrations of adiponectin in mice and humans (7). Circulating adiponectin concentrations are also inversely correlated to triglyceride (8, 9) and intramyocellular lipid stores (10). It has been reported that plasma concentrations of adiponectin are lower in obesity and type 2 diabetes (8,11) and that adipose tissue Acrp30/adiponectin mRNA expression is decreased in obese ob/ob mice and obese humans (12).

The mechanisms underlying the observed close association between plasma adiponectin concentration and lipid metabolism are being elucidated (13,14). In vitro and in vivo studies in rodents have shown that adiponectin prevents lipid accumulation in skeletal muscles in parallel to lowering blood glucose and improving insulin action (14). Recent observations suggest that adiponectin could play a role in counteracting the development of diet-induced insulin resistance (6, 7). It is noteworthy that these actions appear to be independent of the presence of obesity: adiponectin-null mice showed diet-induced insulin resistance despite increases in body weight similar to those in control mice (15,16).

The interaction among diet-induced insulin resistance, adiponectin concentrations, and lipid metabolism could be exerted at the level of the inflammatory cascade. The amount and quality of fat in the diet seem to be of importance for development of insulin resistance and related inflammatory activity (17). A low proportion of long-chain unsaturated fatty acids and a high proportion of saturated fatty acids in the diet have been associated with impaired insulin action (18). Adiponectin possesses antiinflammatory (19) and antiatherogenic properties (20, 21). On the other hand, highly unsaturated fatty acids, [omega]-3 fatty acids in particular, are also receiving increasing attention as potential antiinflammatory agents (22) because these dietary fatty acids appear to modulate the release of different cytokines (23, 24).

How dietary fat may impact on peripheral adiponectin concentration, or vice versa, is unknown. One potential pathway is activation of the nuclear receptor peroxisome proliferator-activated receptor-[gamma] (PPAR-[gamma]). (3) In fact, fatty acids activate PPAR-[gamma] (25), and pharmacologic activation with PPAR-[gamma] agonists leads to increased plasma adiponectin concentrations (26, 27).

Knowledge of the possible influence of dietary habits on circulating adiponectin concentrations could be helpful in delineating dietary measures aimed at preventing type 2 diabetes. However, studies of the associations between dietary habits in relation to the development of chronic diseases are hampered by several methodologic problems, including imprecision of dietary surveys (18). One way to monitor the type of fat in the diet is to record the fatty acid composition in plasma (18). We aimed to evaluate the association between dietary habits, as inferred from plasma fatty acid composition, and circulating adiponectin in healthy individuals.

Materials and Methods


We evaluated 116 individuals as part of an ongoing epidemiologic study dealing with nonclassical cardiovascular risk factors in the general population. All partici pants were of Caucasian origin and reported that their body weight had been stable for at least 3 months before the study. None was taking any medication or had any evidence of metabolic disease other than obesity. Inclusion criteria for this group were (a) body mass index (BMI) <40 kg/[m.sup.2], (b) absence of any systemic disease, and (c) absence of any infections in the previous month. The study was approved by the Hospital Ethics Committee, and informed consent was obtained from all participants.

Anthropometric and clinical measurements. BMI and waistto-hip ratio (WHR) were measured in all participants. BMI was calculated as weight (in kilograms) divided by height (in meters) squared, and participants' waists were measured with a soft tape midway between the lowest rib and the iliac crest. The hip circumference was measured at the widest part of the gluteal region.

Smokers were defined as any person consuming at least one cigarette a day in the previous 6 months. Resting blood pressure was measured by mercury sphygmomanometer after participants had been in a sitting position for a minimum of 15 min. The blood pressure was read three times on the right arm by the same investigator. The mean of the three measurements was used for this study. All women were premenopausal, had regular menstrual cycles, and were studied in their follicular phase. Liver disease and thyroid dysfunction were specifically excluded by biochemical workup.


Analysis of serum fatty acids. Following the method of Lepage and Roy (28), we precisely weighed 100 [micro]L of plasma obtained after a 12-h fast into glass tubes and diluted the plasma with methanol-benzene (4:1 by volume). We slowly added acetyl chloride (200 [micro]L) over a period of 1 min. After transesterification, we dried the pooled solvent extracts under a gentle stream of nitrogen at room temperature. Residues were dissolved in 500 [micro]L of hexane, and an aliquot was injected into the chromatograph. Fatty acids were chromatographed as methyl esters on a 30-m fused-silica column (0.25 mm i.d.). Analysis was performed on a Hewlett-Packard 5890 gas chromatograph equipped with a flame ionization detector. The column temperature was held at 80[degrees]C for 3 min and then increased in a stepwise fashion to a plateau of 220[degrees]C. The injection port and detector temperatures were 250 and 270[degrees]C, respectively. Helium was used as carrier gas. An internal standard consisting of 50 [micro]g of pentadecanoic acid (C15:0) was precisely weighed and added to the serum.

Adiponectin measurements. Plasma adiponectin concentrations were measured by RIA (LINGO Research Inc.). Samples were diluted 500-fold (10 [micro]L of plasma plus 4990 [micro]L of assay buffer) before the assay. The detection limit of s Nonstandard abbreviafions: PPAR-[gamma], peroxisome proliferator-activated receptor-[gamma]; BMI, body mass index; WHR, waist-to-hip ratio; HOMA, homeostasis model assessment; and DHA, docosahexanoic acid. the method is 2 [micro]g/L. The infra- and interassay CVs were <5%.

Measurements of other analytes. The serum glucose concentration was measured in duplicate by the glucose oxidase method.

The serum insulin concentration was measured in duplicate by a monoclonal I1RMA (Medgenix Diagnostics). The lower limit of detection for insulin was 4.0 mN/L. The interassay CV was 5.2% at a concentration of 10 mN/L, and the interassay CV was 6.9% at 14 mN/L. The fasting insulin resistance index [homeostasis model assessment (HOMA)] was calculated with the formula: HOMA = fasting glucose (mmol/L) x fasting insulin (mN/L)/22.5. In our experience, HOMA correlates well with the [S.sub.1] calculated by the minimal model approach: r = 0.79; P <0.0001 (29).

Total serum cholesterol was measured by the reaction of cholesterol esterase/cholesterol oxidase/peroxidase. Total serum triglycerides were measured through the reaction of glycerol-3-phosphate oxidase and peroxidase.


Descriptive results for continuous variables are expressed as the mean (SD). Before statistical analysis, gaussian distribution and homogeneity of the variances were tested. Variables that did not fulfill these tests (individual fatty acids and ratios, HOMA, adiponectin) were logtransformed. The relationships between variables were analyzed by simple correlation analysis (Pearson r). We set statistical significance at P [less than or equal to]0.05 and have based our discussion on these relationships. Participants were divided into quintiles of circulating fatty acids. We compared adiponectin concentrations in individuals in the highest fatty acid quintiles vs the remaining participants with the Student t-test. We also constructed a stepwise multivariate linear regression analysis to predict adiponectin concentrations, taking into consideration those variables with statistical association of at least P <0.1 on univariate analysis. Because in a previous work we found that smoking affected the relationship between inflammatory markers and metabolic variables (30), we also examfined whether smoking (defined as at least 1 cigarette/day in the previous 6 months) affected adiponectin relationships.


The main characteristics and serum fatty acid composition of the study participants are shown in Tables 1 and 2. The absolute fatty acid concentration did not differ significantly between men and women. Circulating adiponectin was significantly higher in women than men (P = 0.006; Table 1). The proportion of saturated acids tended to be lower and the proportion of oleic acid (C18:1 [omega]-9) tended to be higher among women (Table 1). The proportion of eicosanoic acid (C20:1 [omega]-9) was significantly higher in women than men (Table 1). Plasma adiponectin correlated negatively with BMI (r = -0.23; P = 0.01), WHR (r = -0.28; P = 0.002), and fasting plasma triglycerides (r = -0.38; P <0.0001) and tended to be associated with HOMA value (r = -0.16; P = 0.08). Circulating adiponectin was not significantly associated with age, systolic or diastolic blood pressure, fasting glucose, or cholesterol in this series.

The proportion of saturated fatty acids in plasma was significantly associated with circulating adiponectin concentrations (r = -0.24; P = 0.01; Table 3). Specifically, the proportion of palmitic acid (C16:0) was significantly inversely associated with adiponectin concentration (r = -0.28; P = 0.002). This association was significant mainly among women (r = -0.37; P = 0.02) and in nonsmokers (r = -0.30; P = 0.007). The proportion of myristic acid (C14:0) was also significantly inversely associated with adiponectin among nonsmokers (r = -0.26; P = 0.02) and in women (r = -0.39; P = 0.01).

The other individual fatty acids were not significantly associated with adiponectin except for eicosanoic acid (C20:1 [omega]-9), which was significantly and positively associated with adiponectin in all participants (r = 0.23; P = 0.01). This latter association was most significant in smokers (r = 0.43; P = 0.007). C20:1 [omega]-9 was the only fatty acid that was significantly increased in smokers compared with nonsmokers (Table 2). Total monounsaturated [omega]-9 fatty acids were also significantly associated with adiponectin among smokers (Table 3). The proportion of [omega]-3 fatty acids tended to be positively associated with adiponectin in nonsmokers (r = 0.21; P = 0.07).

We next divided our population into quintiles for the different fatty acids. As anticipated from the correlation analysis, individuals in the two highest quintiles for percentage of palmitic acid had significantly decreased serum adiponectin concentrations compared with the remaining individuals [13.9 (4.8) vs 16.4 (5.28) mg/L; P = 0.006; Fig. 1]. Not apparent from the correlation analysis were the following findings: individuals in the highest quintile of docosahexanoic acid (DHA; C22:6) had significantly increased circulating adiponectin concentrations compared with the remaining participants [18.02 (4.8) vs 14.76 (4.9) mg/L; P = 0.018; Fig. 1]; and individuals in the highest quintile of [gamma]-linolenic acid (C18:3 [omega]-6) had significantly decreased serum adiponectin compared with the remaining participants [12.1 (3.6) vs 15.4 (5) mg/L; P = 0.04].


The ratio of saturated/([omega]]-3) fatty acids correlated positively with both HOMA value (r = 0.19; P = 0.03) and circulating adiponectin concentrations (r = -0.19; P = 0.03).

We performed several multivariate regression analyses to predict circulating adiponectin concentrations. In these models, we considered as independent variables those individual fatty acids that showed a relationship with at least P <0.1 on univariate analysis. After controlling for age, BMI, WHR (which persisted in the model), and the individual remaining fatty acids, only the proportions of palmitic acid (C16:0; P = 0.005) and eicosanoic acid (C20:1 [omega]-9; P = 0.03) contributed independently to adiponectin variance (6% and 3%,respectively).

Among nonsmokers, and after again controlling for age, BMI, WHR (which persisted in the model), and the remaining individual fatty acids, only the proportions of palmitic acid (C16:0; P = 0.01) and [omega]-3 fatty acids contributed to adiponectin variance (8% and 7%,respectively).

Among smokers, only the proportion of eicosanoic acid (C20:1 [omega]-9; P = 0.03) contributed to adiponectin variance (10%), independently of BMI, age, WHR, and the remaining individual fatty acids. Of the remaining factors, only WHR persisted in the model.


The proportions of fatty acids in plasma mirror the dietary fat composition. The relationships between the amount of polyunsaturated fatty acids in the diet and the corresponding proportions of the same fatty acids in plasma lipids are often strong (18). This is usually true for essential fatty acids, such as linoleic and [alpha]-linolenic acid. However, most other types of fatty acids can be synthesized by humans from precursors, particularly saturated fatty acids.

Adiponectin was negatively associated with the main saturated acid, palmitic acid (C16:0). In a recent in vitro study, saturated fatty acids induced activation of nuclear factor-KB, an important mediator in the production of several cytokines (31), whereas DHA counteracted these effects (31, 32). To our knowledge, the possible actions of saturated fatty acids on adiponectin production have not been evaluated. Our findings suggest that increased intake of saturated fatty acids and increased endogenous transformation of fatty acids that leads to increased concentrations of saturated fatty acids in plasma are associated with decreased circulating adiponectin concentrations. Cause and consequence cannot be derived from the present study. It could be hypothesized that decreased adiponectin concentrations amplify the proinflammatory action of saturated fatty acids.

Adiponectin was positively associated with the proportion of C20:1 [omega]-9. This association was especially significant in smokers (P = 0.007). Although BMI tended to be lower with increased proportions of C20:1 [omega]-9, the association remained significant after controlling for BMI (r = 0.25; P = 0.008). Interestingly, significantly increased products of delta-9 desaturation and significant increases in C20 elongation products have been observed in rats with reduced food intake (33). On the other hand, smoking has been found to be associated with a decreased proportion of essential fatty acids (34), and essential fatty acid deficiency leads to a characteristic increase in [omega]-9 fatty acids (35). Because caloric restriction can lead to higher circulating concentrations of adiponectin in mice and humans (7), it is tempting to speculate that reduced food intake leads to increased adiponectin and C20:1 [omega]-9 concentrations concomitantly.

As secondary findings, we found that those individuals with an increased proportion of C18:3 [omega]-6 had concomitantly decreased circulating adiponectin concentrations. The content of this fatty acid is typically very small in the diet. Rather, it reflects increased endogenous desaturation of linoleic acid by delta-6 desatorase, increasing the proportion of C18:3 [omega]-6, probably as a consequence of a low proportion of linoleic acid in the diet (18). Our findings suggest that low intake of this essential fatty acid could lead to increased C18:3 [omega]-6 and concomitant decreased adiponectin concentrations.

We also show that the proportions of [omega]-3 fatty acids in general, and of DHA in particular, were highest in those individuals with increased circulating adiponectin. In nonsmokers, this association persisted after controlling for age, BMI, WHR, and the remaining individual fatty acids. Interestingly, two putative antiinflammatory molecules, [omega]-3 fatty acids and adiponectin, seem to be linked. The same processes and dietary habits that increase the concentrations of [omega]-3 fatty acids lead to concomitant increased adiponectin concentrations. In recent years, novel functional sets of lipid-derived mediators with antiinflammatory actions generated from [omega]-3 fatty acids have been increasingly recognized (22). The association of the proportions of [omega]-3 and adiponectin described here seems particularly important in light of recent findings in American women: Increased intake of the [omega]-3 polyunsaturated fatty acids eicosapentanoic (C20:5 [omega]-3) and DHA (C22:6 [omega]-3) was associated with reduced risk of thrombotic diseases (26). In parallel with these observations, the authors of in vitro and in vivo studies in humans reported that supplementation with eicosapentanoic acid and DHA appeared to reduce cytokine production (23, 24, 31, 3638). The above relationships were most likely to have a dietary explanation because food is the major source of these fatty acids (18). Adiponectin also has antiatherogenic properties and inhibits proliferation of vascular smooth muscle cell (16). Inflammation in the vessel wall plays an essential part in the initiation and progression of atherosclerosis (39, 40). Decreased adiponectin concentrations have been observed in patients with coronary artery disease (8). The findings of the present study suggest that all of these associations are interrelated events.

An association between concentrations of fasting plasma triglycerides and adiponectin has also been observed (9). Different studies have shown that adiponectin promotes lipid oxidation in humans, with a subsequent decrease in intracellular lipid content in human muscle (10). These results are consistent with animal data: Adiponectin was shown to enhance lipid oxidation and decrease the concentration of muscle triglycerides (5,13).

One limitation of this study is its transversal design; thus, the findings shown here are hypothesis-generating. It will be necessary to demonstrate that adiponectin concentrations can be modulated by ingestion of certain fatty acids or by changing of serum fatty acid composition. In addition, fatty acids were measured in plasma, but it is well known that fatty acids are also a major component of the cell membranes. Fatty acids measured in cell membranes may better reflect longer-term dietary fatty acid intake because fatty acid turnover may be slower in cell membranes than in plasma.

In summary, saturated and [omega]-3 fatty acids of dietary origin (as inferred from plasma fatty acid concentration) are associated with circulating adiponectin concentrations in healthy humans. The proportion of C20:1 [omega]-9 also appears to be positively associated with circulating adiponectin. The knowledge of how these interactions occur will be helpful in the planning of dietary measures aimed at the modulation of inflammatory activity.

This work was partially supported by Grant 00/0024-01 from the Fondo de Investigaciones Sanitarias, National Health Institute of Spain, and by Grants RGDM G03/212 and RGTO G03/028 from the Instituto de Salud Carlos III, Madrid, Spain.

Received August 9, 2004; accepted December 14, 2004. Previously published online at DOI: 10.1373/clinchem.2004.041350


(1.) Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24: 278-301.

(2.) Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose Most abundant Gene transcript 1). Biochem Biophys Res Common 1996;221:286-9.

(3.) Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-9.

(4.) Hoffstedt J, Arvidsson E, Sjolin E, Wahlen K, Arner P. Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance. J Clin Endocrinol Metab 2004;89:1391-6.

(5.) Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001;98:2005-10.

(6.) Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7: 941-6.

(7.) Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocytesecreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7:947-53.

(8.) Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.

(9.) Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002;87:2764-9.

(10.) Thamer C, Machann J, Tschritter 0, Haap M, Wietek B, Dahl D, et al. Relationship between serum adiponectin concentration and intramyocellular lipid stores in humans. Horm Metab Res 2002; 34:646-9.

(11.) Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.

(12.) Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-703.

(13.) Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8: 1288-95.

(14.) Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 2002;99:16309-13.

(15.) Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin. Nat Med 2002;8:731-7.

(16.) Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002;277:25863-6.

(17.) Fernandez-Real JM, Broch M, Vendrell J, Ricart W. Insulin resistance, inflammation and serum fatty acid composition. Diabetes Care 2003;26:1362-8.

(18.) Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 2003;14:15-9.

(19.) Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomono cytic progenitors and the functions of macrophages. Blood 2000; 96:1723-32.

(20.) Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator of endothelial adhesion molecules: adipocytederived plasma protein adiponectin. Circulation 1999;100: 2473-6.

(21.) Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NK-KB signaling through a camp-dependent pathway. Circulation 2000;102:1296-301.

(22.) Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antunflammatory actions generated from omega-3 fatty acids via cyclooxygen ase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000;192:1197-204.

(23.) Meydani SN. Modulation of cytokine production by dietary polyunsaturated fatty acids. Proc Soc Exp Biol Med 1992;200:189-93.

(24.) Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-71.

(25.) Krey G, Braissant 0, L'Horset F, Kalkhoven E, Perroud M, Parker MG, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated recep toys by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997;11:779-91.

(26.) Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARy ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-9.

(27.) Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino U, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:4312-9.

(28.) Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 1986;27:114-20.

(29.) Fernandez-Real JM, Molina A, Broch M, Ricart W, Gutierrez C, Casamitjana R, et al. The TNF system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. Diabetes 1999;48:1108-12.

(30.) Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001;86:1154-9.

(31.) Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through toll-like receptor 4. J Biol Chem 2001; 276:16683-9.

(32.) De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr 2000;71:213-23.

(33.) Kramer TR, Briske-Anderson M, Johnson SB, Holman RT. Influence of reduced food intake on polyunsaturated fatty acid metabolism in zinc-deficient rats. J Nutr 1984;114:1224-30.

(34.) Leng GC, Smith FB, Fowkes FG, Horrobin DF, Ells K, Morse-Fisher N, et al. Relationship between plasma essential fatty acids and smoking, serum lipids, blood pressure and haemostatic and Theological factors. Prostaglandins Leukot Essent Fatty Acids 1994; 51:101-8.

(35.) Soriguer F, Moreno F, Rojo-Martinez G, Garcia-Fuentes E, Tinahones F, Gomez-Zumaquero JM, et al. Monounsaturated n-9 fatty acids and adipocyte lipolysis in rats. Br J Nutr 2003;90:1015-22.

(36.) Iso H, Rexrode KM, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA 2001;285:304-12.

(37.) Khalfoun B, Thibault F, Watier H, Bardos P, Lebranchu Y. Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Adv Exp Med Biol 1997;400B:589-97.

(38.) Loppnow H, Libby P. Comparative analysis of cytokine induction in human vascular endothelial and smooth muscle cells. Lymphokine Res 1989;8:293-9.

(39.) Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, et al. Interleukin-6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994;6:87-91.

(40.) Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.


[1] Section of Diabetes, Endocrinology and Nutrifion, University Hospital of Girona "Dr Josep Trueta", Girona, Spain.

[2] Section of Diabetes, Endocrinology and Nutrifion, University Hospital of Tarragona, Tarragona, Spain.

* Address correspondence to this author at: Unitat d'Endocrinologia, Diabetes i Nutricio, Hospital de Girona, Carretera de Francia s/n, 17007 Girona, Spain. Fax 34-972-940270; e-mail
Table 1. Anthropometric and biochemical variables. (a)

 Men Women P

Number 76 40
Age, years 40.3 (12.2) 36.3 (10.8) NS (b)
Weight, kg 75.3 (12) 60.9 (10.3) 0.0001
BMI, kg/[m.sup.2] 24.9. (3.7) 23.2 (4.3) 0.02
WHR 0.97 (0.05) 0.85 (0.04) 0.0001
Blood pressure, mmHg
 Systolic 122.9 (14) 115.5 (16) 0.009
 Diastolic 70.9 (9) 65.4 (8.5) 0.001
Fasting glucose, mmol/L 4.9 (0.6) 4.6 (0.6) 0.03
Fasting insulin, mlU/L 7.3 (3.7) 6.7 (3) NS
HOMA value 1.48 (0.9) 1.28 (0.7) NS
Cholesterol, mg/L 2180 (450) 2020 (440) 0.04
Triglycerides, mg/L 1180 (700) 700 (240) 0.0001
Adiponectin, mg/L 14.5 (4.7) 17.2 (5.2) 0.006
Fatty acids, % of total
fatty acids
 14:0 0.45 (0.29) 0.51 (0.37) NS
 16:0 20.1 (2.2) 19.4 (4.1) NS
 16:1 ([omega]-9) 0.38 (0.11) 0.38 (0.10) NS
 18:0 7.73 (0.72) 7.44 (1.1) NS
 18:1 ([omega]-9) 20.8 (3.7) 22.9 (9) 0.07
 18:2 ([omega]-6) 31.3 (4.9) 30.6 (7) NS
 18:3 ([omega]-6) 0.44 (0.14) 0.43 (0.16) NS
 18:3 ([omega]-3) 0.28 (0.10) 0.34 (0.37) NS
 20:0 0.30 (0.07) 0.28 (0.08) NS
 20:1 ([omega]-9) 0.10 (0.09) 0.15 (0.12) 0.023
 20:3 ([omega]-9) 1.56 (0.4) 1.44 (0.3) 0.09
 20:4 ([omega]-6) 7.21 (1.39) 6.93 (1.42) NS
 20:5 ([omega]-3) 0.57 (0.41) 0.56 (0.38) NS
 22:0 0.85 (0.18) 0.80 (0.16) NS
 22:6 ([omega]-3) 2.02 (0.69) 1.94 (0.64) NS
 24:0 1.06 (0.16) 1.04 (0.20) NS
 24:1 ([omega]-9) 1.23 (0.36) 1.22 (0.32) NS
 Essential fatty acids 43.0 (5.1) 41.8 (7.6) NS
 Saturated fatty acids 30.8 (2.0) 29.8 (4.6) 0.09
 Monounsaturated ([omega]-9) 22.4 (4.66) 22.6 (4.23) NS
 Polyunsaturated ([omega]-3) 2.88 (0.9) 2.8 (1) NS
 Polyunsaturated ([omega]-6) 40.1 (5.2) 39 (7.6) NS

(a) Values are the mean (SD).

(b) NS, not significant.

Table 2. Plasma fatty acid profile according to
smoking status.

 Relative concentration,
 (a) %

 Nonsmokers Smokers
Fatty acid (n = 78) (n = 38) P

14:0 0.45 (0.29) 0.51 (0.37) NS (b)
16:0 20.1 (2.2) 19.4 (4.1) NS
16:1 ([omega]-9) 0.38 (0.11) 0.38 (0.10) NS
18:0 7.73 (0.72) 7.44 (1.1) NS
18:1 ([omega]-9) 20.8 (3.7) 22.9 (9) 0.07
18:2 ([omega]-6) 31.3 (4.9) 30.6 (7) NS
18:3 ([omega]-6) 0.44 (0.14) 0.43 (0.16) NS
18:3 ([omega]-3) 0.28 (0.10) 0.34 (0.37) NS
20:0 0.30 (0.07) 0.28 (0.08) NS
20:1 ([omega]-9) 0.10 (0.09) 0.15 (0.12) 0.023
20:3 ([omega]-6) 1.48 (0.4) 1.60 (0.39) NS
20:4 ([omega]-6) 7.21 (1.39) 6.93 (1.42) NS
20:5 ([omega]-3) 0.57 (0.41) 0.56 (0.38) NS
22:0 0.85 (0.18) 0.80 (0.16) NS
22:6 ([omega]-3) 2.02 (0.69) 1.94 (0.64) NS
24:0 1.06 (0.16) 1.04 (0.20) NS
24:1 ([omega]-9) 1.23 (0.36) 1.22 (0.32) NS
Essential fatty acids 43.0 (5.1) 41.8 (7.6) NS
Saturated fatty acids 30.8 (2.0) 29.8 (4.6) 0.09
Monounsaturated 22.4 (4.66) 22.6 (4.23) NS
Polyunsaturated ([omega]-3) 2.88 (0.9) 2.8 (1) NS
Polyunsaturated ([omega]-6) 40.1 (5.2) 39 (7.6) NS

(a) Values are the mean (SD).

(b) NS, not significant.

Table 3. Correlations between serum fatty acids and adiponectin. (a)

Fatty acid All (n = 116) Men (n = 76)

 r P r P

14:0 -0.11 0.2 -0.01 0.8
16:0 -0.28 0.002 -0.10 0.3
16:1 ([omega]-9) 0.04 0.6 -0.06 0.5
18:0 0.08 0.3 0.15 0.1
18:1 ([omega]-9) 0.08 0.3 0.08 0.4
18:2 ([omega]-6) -0.01 0.9 -0.10 0.3
18:3 ([omega]-3) 0.01 0.8 -0.05 0.6
18:3 ([omega]-6) -0.05 0.5 -0.004 0.9
20:0 0.04 0.6 0.02 0.8
20:1 ([omega]-9) 0.23 0.01 0.12 0.2
20:3 ([omega]-6) 0.09 0.32 0.10 0.3
20:4 ([omega]-6) 0.02 0.78 0.02 0.8
20:5 ([omega]-3) 0.09 0.3 0.09 0.4
22:0 0.11 0.2 0.11 0.3
22:6 ([omega]-3) 0.06 0.4 0.08 0.4
24: 0.06 0.4 0.07 0.4
24:1 ([omega]-9) 0.06 0.5 -0.002 0.9
Essential fatty acids 0.01 0.8 -0.06 0.5
Saturated fatty acids -0.24 0.01 -0.04 0.7
Monounsaturated ([omega]-9) 0.08 0.3 0.08 0.4
Polyunsaturated ([omega]-3) 0.08 0.3 0.09 0.4
Polyunsaturated ([omega]-6) 0.001 0.9 -0.07 0.4

Fatty acid Women (n = 40) Nonsmokers
 (n = 78)

 r P r P

14:0 -0.39 0.01 -0.26 0.02
16:0 -0.37 0.02 -0.30 0.007
16:1 ([omega]-9) -0.04 0.8 0.06 0.5
18:0 0.13 0.4 0.03 0.7
18:1 ([omega]-9) 0.01 0.9 0.02 0.8
18:2 ([omega]-6) 0.18 0.26 0.05 0.6
18:3 ([omega]-3) -0.002 0.9 0.04 0.7
18:3 ([omega]-6) -0.12 0.4 -0.09 0.4
20:0 0.22 0.1 0.01 0.8
20:1 ([omega]-9) 0.16 0.32 0.5 0.6
20:3 ([omega]-6) 0.24 0.1 0.05 0.6
20:4 ([omega]-6) 0.10 0.5 0.10 0.3
20:5 ([omega]-3) 0.11 0.4 0.08 0.4
22:0 0.24 0.1 0.13 0.2
22:6 ([omega]-3) 0.09 0.5 0.11 0.3
24: 0.12 0.4 0.08 0.4
24:1 ([omega]-9) 0.25 0.1 0.09 0.4
Essential fatty acids 0.21 0.1 0.10 0.3
Saturated fatty acids -0.31 0.05 -0.20 0.07
Monounsaturated ([omega]-9) 0.01 0.9 0.02 0.8
Polyunsaturated ([omega]-3) 0.10 0.5 0.21 0.07
Polyunsaturated ([omega]-6) 0.19 0.2 0.08 0.4

Fatty acid Smokers (n = 38)

 r P

14:0 0.05 0.7
16:0 -0.22 0.1
16:1 ([omega]-9) 0.002 0.9
18:0 0.21 0.1
18:1 ([omega]-9) 0.23 0.09
18:2 ([omega]-6) -0.20 0.2
18:3 ([omega]-3) -0.15 0.3
18:3 ([omega]-6) 0.06 0.6
20:0 0.08 0.5
20:1 ([omega]-9) 0.43 0.007
20:3 ([omega]-6) 0.18 0.27
20:4 ([omega]-6) -0.17 0.2
20:5 ([omega]-3) 0.11 0.4
22:0 0.05 0.7
22:6 ([omega]-3) -0.06 0.7
24: 0.03 0.8
24:1 ([omega]-9) -0.04 0.8
Essential fatty acids -0.21 0.1
Saturated fatty acids -0.16 0.3
Monounsaturated ([omega]-9) 0.34 0.03
Polyunsaturated ([omega]-3) 0.001 0.9
Polyunsaturated ([omega]-6) -0.21 0.2

(a) Bold font indicates fatty acids significantly correlated with
adiponectin concentrations.
COPYRIGHT 2005 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Endocrinology and Metabolism
Author:Fernandez-Real, Jose-Manuel; Vendrell, Joan; Ricart, Wifredo
Publication:Clinical Chemistry
Date:Mar 1, 2005
Previous Article:Quantification of antimalarial Bisthiazolium compounds and their neutral bioprecursors in plasma by liquid chromatography-electrospray mass...
Next Article:2-ethylhydracrylic aciduria in short/branched-chain acyl-CoA dehydrogenase deficiency: application to diagnosis and implications for the R-pathway of...

Related Articles
Erythrocyte fatty acid composition and the metabolic syndrome: a National Heart, Lung, and Blood Institute GOLDN study.
Prevalence and cluster of cardiometabolic biomarkers in overweight and obese schoolchildren: results from a large survey in southwest Germany.
Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin.
Retinol-binding protein 4 and lipocalin-2 in childhood and adolescent obesity: when children are not just "small adults".
Adiponectin: a promising marker for cardiovascular disease.
Adiponectin, adipocyte fatty acid binding protein, and epidermal fatty acid binding protein: proteins newly identified in human breast milk.
Interaction of the -308G/A promoter polymorphism of the tumor necrosis factor-[alpha] gene with single-nucleotide polymorphism 45 of the adiponectin...
The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity.
Circuit resistance exercise improves glycemic control and adipokines in females with type 2 diabetes mellitus.
An overlooked risk factor in heart disease: an interview with Sarah Berry, M.D.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters